ATE118772T1 - Verfahren zur herstellung von (4r-cis)-1,1- dimethylethyl-6-cyanmethyl-2,2-dimethyl-1,3- dioxan-4-acetat. - Google Patents

Verfahren zur herstellung von (4r-cis)-1,1- dimethylethyl-6-cyanmethyl-2,2-dimethyl-1,3- dioxan-4-acetat.

Info

Publication number
ATE118772T1
ATE118772T1 AT91919118T AT91919118T ATE118772T1 AT E118772 T1 ATE118772 T1 AT E118772T1 AT 91919118 T AT91919118 T AT 91919118T AT 91919118 T AT91919118 T AT 91919118T AT E118772 T1 ATE118772 T1 AT E118772T1
Authority
AT
Austria
Prior art keywords
dimethylethyl
dioxane
cis
dimethyl
acetate
Prior art date
Application number
AT91919118T
Other languages
English (en)
Inventor
Alan Millar
Donald Eugene Butler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE118772T1 publication Critical patent/ATE118772T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT91919118T 1990-10-17 1991-09-11 Verfahren zur herstellung von (4r-cis)-1,1- dimethylethyl-6-cyanmethyl-2,2-dimethyl-1,3- dioxan-4-acetat. ATE118772T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/599,521 US5103024A (en) 1990-10-17 1990-10-17 Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Publications (1)

Publication Number Publication Date
ATE118772T1 true ATE118772T1 (de) 1995-03-15

Family

ID=24399962

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919118T ATE118772T1 (de) 1990-10-17 1991-09-11 Verfahren zur herstellung von (4r-cis)-1,1- dimethylethyl-6-cyanmethyl-2,2-dimethyl-1,3- dioxan-4-acetat.

Country Status (19)

Country Link
US (1) US5103024A (de)
EP (1) EP0553213B1 (de)
JP (1) JP3105923B2 (de)
KR (1) KR0166385B1 (de)
AT (1) ATE118772T1 (de)
AU (1) AU646311B2 (de)
CA (1) CA2092997C (de)
CZ (5) CZ282922B6 (de)
DE (1) DE69107622T2 (de)
DK (1) DK0553213T3 (de)
ES (1) ES2070519T3 (de)
FI (1) FI108539B (de)
HU (2) HU219237B (de)
IE (1) IE62940B1 (de)
NO (1) NO301588B1 (de)
PT (1) PT99244B (de)
RU (1) RU2067580C1 (de)
SK (5) SK280939B6 (de)
WO (1) WO1992006968A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
ES2207202T3 (es) * 1998-04-30 2004-05-16 Kaneka Corporation Procedimiento para producir derivados de acido 6-cianometil-1, 3-dioxano-4-acetico.
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
CA2391357C (en) 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
ES2252088T3 (es) 1999-12-17 2006-05-16 Pfizer Science And Technology Ireland Limited Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina.
US7521216B2 (en) * 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 ３，５，６−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
EP1734034A3 (de) 2001-01-09 2007-01-03 Warner-Lambert Company LLC Carbonsäuresalze von beta-Alaninestern oder -Amiden
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
HUP0400381A2 (hu) * 2001-06-29 2004-09-28 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
GB0116212D0 (en) * 2001-07-03 2001-08-29 Avecia Ltd Process
EE200400048A (et) 2001-07-30 2004-04-15 Dr. Reddy's Laboratories Ltd. Atorvastatiinkaltsiumi kristalsed vormid VI ja VII
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
EP1323717A1 (de) * 2001-12-27 2003-07-02 Dsm N.V. Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
AU2003251523A1 (en) 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
EP1375493A1 (de) * 2002-06-17 2004-01-02 Dsm N.V. Verfahren zur Herstellung von Dioxanessigsäureester
CN100357289C (zh) * 2002-08-06 2007-12-26 沃尼尔·朗伯有限责任公司 制备5－(4－氟苯基)－1－[2－((2r,4r)－4－羟基－6－氧代－四氢－吡喃－2－基)乙基]－2－异丙基－4－苯基－1h－吡咯－3－羧酸苯基酰胺的方法
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
KR100529703B1 (ko) * 2002-09-23 2005-11-17 임광민 키랄 중간체의 제조방법 및 그를 이용한 아토바스타틴의제조방법
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
RS20050760A (sr) * 2003-04-14 2008-04-04 Warner-Lambert Company Llc., Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EP1626713A2 (de) * 2003-05-16 2006-02-22 Ambit Biosciences Corporation Heterocyclische verbindungen und ihre verwendungen
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP2522656A3 (de) 2003-07-25 2013-03-20 Redx Pharma Limited Verfahren und Intermediate zur Herstellung von Statinen, insbesondere Atorvastatin
GB0317393D0 (en) * 2003-07-25 2003-08-27 Avecia Ltd Process and compounds
US20070276027A1 (en) * 2003-09-17 2007-11-29 Warner-Lambert Company Llc Crystalline Forms of [R-(R* ,R*)]-2-(4-Fluorophenyl)-Beta, -Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CA2666359A1 (en) 2004-03-17 2005-10-06 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
AU2005232959A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006021969A1 (en) * 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
EP1807055A1 (de) * 2004-10-28 2007-07-18 Warner-Lambert Company LLC Verfahren zur herstellung von amorphem atorvastatin
AU2005305460B2 (en) 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
EP1922315B1 (de) * 2005-09-09 2009-05-27 Pfizer Science and Technology Ireland Limited Herstellung eines atorvastatin-zwischenprodukts
WO2007029217A1 (en) * 2005-09-09 2007-03-15 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US9217164B2 (en) 2007-03-01 2015-12-22 Basf Enzymes Llc Nitrilases, nucleic acids encoding them and methods for making and using them
WO2009013633A2 (en) * 2007-07-20 2009-01-29 Actavis Group Ptc Ehf Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
EP2075246A1 (de) 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
SI2614057T1 (sl) 2010-09-09 2016-03-31 Dsm Sinochem Pharmaceuticals Netherlands B.V. Soli estrov 7-amino-3,5-dihidroksi heptanojske kisline
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
WO2016056031A1 (en) 2014-10-08 2016-04-14 Council Of Scientific & Industrial Research Novel diol compounds synthesis and its use for formal synthesis of (2r, 3 s)-3-hydroxypipecolic acid
CN106008251A (zh) * 2016-05-19 2016-10-12 河南豫辰药业股份有限公司 一种2-苯甲撑-3-氧代-4-甲基-n-苯基戊酰胺的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5093363A (en) * 1989-08-22 1992-03-03 Shionogi & Co., Ltd. 2,4,6-substituted phenol derivatives
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte

Also Published As

Publication number Publication date
KR930702328A (ko) 1993-09-08
EP0553213B1 (de) 1995-02-22
IE62940B1 (en) 1995-03-08
KR0166385B1 (en) 1999-01-15
CZ282994B6 (cs) 1997-12-17
ES2070519T3 (es) 1995-06-01
CZ282993B6 (cs) 1997-12-17
EP0553213A1 (de) 1993-08-04
CZ282992B6 (cs) 1997-12-17
SK280942B6 (sk) 2000-09-12
US5103024A (en) 1992-04-07
DE69107622T2 (de) 1995-07-06
CZ282922B6 (cs) 1997-11-12
HU9301122D0 (en) 1993-08-30
HU219237B (en) 2001-03-28
IE913629A1 (en) 1992-04-22
PT99244B (pt) 1999-04-30
FI108539B (fi) 2002-02-15
NO931421L (no) 1993-06-16
JPH06502162A (ja) 1994-03-10
CZ124697A3 (en) 1997-12-17
DK0553213T3 (da) 1995-07-17
CZ61493A3 (en) 1994-02-16
HK1005026A1 (en) 1998-12-18
CZ124597A3 (en) 1997-12-17
FI931680L (fi) 1993-04-14
WO1992006968A1 (en) 1992-04-30
JP3105923B2 (ja) 2000-11-06
AU646311B2 (en) 1994-02-17
RU2067580C1 (ru) 1996-10-10
DE69107622D1 (de) 1995-03-30
CA2092997A1 (en) 1992-04-18
CA2092997C (en) 2002-05-14
PT99244A (pt) 1992-09-30
SK280940B6 (sk) 2000-09-12
HU9701183D0 (en) 1997-09-29
CZ209495A3 (en) 1997-12-17
NO931421D0 (no) 1993-04-16
SK280938B6 (sk) 2000-09-12
AU8848091A (en) 1992-05-20
SK280939B6 (sk) 2000-09-12
HU213731B (en) 1997-09-29
HUT64049A (en) 1993-11-29
FI931680A0 (fi) 1993-04-14
CZ283003B6 (cs) 1997-12-17
NO301588B1 (no) 1997-11-17
SK33993A3 (en) 1993-10-06
SK280941B6 (sk) 2000-09-12
CZ124797A3 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
ATE118772T1 (de) Verfahren zur herstellung von (4r-cis)-1,1- dimethylethyl-6-cyanmethyl-2,2-dimethyl-1,3- dioxan-4-acetat.
ATE121066T1 (de) Verfahren zur herstellung von 6,12-dihydro-6- hydroxy-cannabidiol und dessen anwendung zur herstellung von trans-delta-9- tetrahydrocannabinol.
ATE137493T1 (de) Verfahren zur herstellung von zwischenprodukten zur verwendung in der herstellung von alkoxyiminoacetamide
EP1491204A4 (de) Verfahren zur herstellung einer fettzusammensetzung mit hydrophoben komponenten von glycyrrhiza
ATE226940T1 (de) Verfahren zur herstellung von d-threo-(r,r)- methylphenidat und recycling nicht erwünschter enantiomere durch epimerisierung
ATE190050T1 (de) Verfahren zur herstellung von 2-acetyl-1-pyrrolin in verkapselter form, zwischenprodukte und endprodukt
AT375378B (de) Verfahren zur herstellung von 4'-deoxydaunorubicin
DE59007171D1 (de) Verfahren zur herstellung von sclareolid.
ATE216231T1 (de) Verfahren zur herstellung von avermectin/zein- zusammensetzungen
DE3576952D1 (de) Verfahren zur herstellung von 4-phenyl-pyrrol-derivaten.
AT362777B (de) Verfahren zur herstellung von 4-(6'-methoxy-2'naphthyl)-butan-2-on
ATE117994T1 (de) Verfahren zur herstellung von 2-chlor-5- chlormethylpyridin.
DE69415345D1 (de) Verfahren zur herstellung von bisnoraldehyden aus bisnoralkohol
ATA240890A (de) Verfahren zur herstellung eines zwischenproduktes von diltiazem
DE3764875D1 (de) Verfahren zur herstellung von penemderivaten.
ATE207139T1 (de) Verfahren zur herstellung von butantetracarbonsäure
ATE100148T1 (de) Verfahren zur herstellung von hochgradig ungesaettigten fettsaeuren.
DE69003957D1 (de) Verfahren zur Herstellung von gereinigten, fetten Alkyldiethanolamiden, die daraus hergestellten Produkte und ihre Verwendung.
DE3582345D1 (de) Verfahren zur herstellung eines optisch aktiven lactons und neue zwischenprodukte in diesem verfahren.
ATE139231T1 (de) Verfahren zur herstellung von castanospermin
DE69510787D1 (de) Verfahren zur herstellung von 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanonderivative
DE3870829D1 (de) Enantioselektives verfahren zur herstellung von trans- oder cis-hemicaronaldehyd-derivaten und erhaltene zwischenprodukte.
ATE138903T1 (de) Verfahren zur herstellung von substituierten vinylbenzolen
DE69729631D1 (de) Verfahren zur herstellung von granisetron
ATE134993T1 (de) Verfahren zur herstellung von cyclopropannitrilderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee